{"database": "openregs", "table": "documents", "rows": [["FDA-2021-D-0691-0013", "FDA", "FDA-2021-D-0691", "Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 or Programmed Cell Death-Ligand 1 Blocking Antibodies for Treatment of Patients With Cancer; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-12-06T05:00:00Z", 2022, 12, "2022-12-06T05:00:00Z", null, "2022-12-06T13:06:58Z", "2022-26464", 0, 0, "090000648551cdc8"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2021-D-0691-0013"], "units": {}, "query_ms": 5.3573630284518, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}